Market Overview

Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O'Connor

Share:

Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early
Development and Neurology, Vertex

Jack Hoppin, Ph.D., Co-Founder & Chief Executive Officer, Invicro

Sue O'Connor, B.Sc. (Hons), Ph.D., Vice President,
Neuroscience Research, Bionomics

BIOASIS
TECHNOLOGIES INC
. ((TSX.V:BTI, OTCQB:BIOAF), a biopharmaceutical
company developing xB3 TM, a proprietary platform technology
for the delivery of therapeutics across the blood-brain barrier (BBB)
and the treatment of CNS disorders, including brain cancers and
neurodegenerative diseases, today announced the addition of Mario
Saltarelli, M.D., Ph.D., senior vice president of early development and
neurology at Vertex Pharmaceuticals Incorporated, Jack Hoppin, Ph.D.,
co-founder and chief executive officer at Invicro, and Sue O'Connor,
B.Sc. (Hons), Ph.D., vice president of neuroscience research at
Bionomics, to its scientific advisory board (SAB). The Bioasis SAB is
chaired by Professor
John H. Krystal, M.D.
, chair of the department of psychiatry and
professor of neuroscience, Yale University School of Medicine and chief
of psychiatry, Yale-New Haven Hospital. Additional Bioasis SAB members
include Jeffrey
L. Cummings, M.D.
and John
P. Wikswo, Jr., Ph.D.
The first Bioasis SAB will convene on Fri.,
July 6, 2018.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180612005541/en/

Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early Development & Neurology, Vertex Pharmace ...

Mario Saltarelli, M.D., Ph.D., Senior Vice President, Early Development & Neurology, Vertex Pharmaceuticals Incorporated (Photo: Business Wire)

"I've been fortunate to have worked with Mario while at Abbott and with
Jack since he founded Invicro in 2008. I first met Sue at Bionomics in
my role as head of neuroscience business development at Bristol Myers
Squibb. On behalf of Professor John Krystal and I, we are delighted to
welcome Mario, Sue and Jack to the Bioasis SAB," said Mark Day, Ph.D.,
president and chief executive officer, Bioasis.

"Mario has more than two decades of exceptional industry leadership,"
said Dr. Day. "Mario's extensive medical science, global clinical drug
development, scientific and regulatory clinical program design expertise
in diseases related to the central nervous system will be tremendously
valuable as we advance our in-house programs."

"The Bioasis team is truly focused - everything they do is dedicated to
bringing new medicines to patients suffering from neurological diseases
as quickly as possible," said Dr. Saltarelli. "I am eager to work with
this SAB to guide the team's pre-clinical models to help predict how the
medicines will perform in patients for a higher probability of success."

"Jack's translational science and drug development expertise,
specifically in translatable quantitative biomarker strategies for
diseases related to the central nervous system, is directly aligned with
our focus on delivering medicines across the blood-brain barrier to
treat neurological diseases and disorders," said Dr. Day. "As we move
closer to the next phases of our in-house development programs, we look
forward to his insightful contributions with a key focus on imaging
bioinformatics in drug development and discovery in the areas of brain
cancers and neurodegeneration, to the Bioasis SAB."

"Bioasis has a unique and versatile approach to delivering therapeutics
across the blood-brain barrier and into the brain, a solution to a
problem that has blocked development of effective treatments for
neurological disorders," said Dr. Hoppin. "I am thrilled to work with
Mark again and I look forward to contributing to the company's focus on
translational medicine and biomarker strategies to advance its clinical
pipeline."

"Sue is an exceptional scientist and has been a major contributor to the
translation of preclinical discovery programs to clinical stage," said
Dr. Day. "Sue brings extensive, relevant discovery and clinical
development expertise to this SAB and shares our dedication to discover
and develop effective therapies for brain-related diseases. Moreover,
Sue and her colleagues have built a robust preclinical and clinical
portfolio that I consider to be a best-in-class CNS pipeline."

"I am truly excited to join the Bioasis SAB and to be involved with this
innovative company with such tremendous potential," said Dr. O'Connor.
"I share the team's conviction and approach to tackle these important
clinical programs in brain cancer and neurodegenerative diseases. I am
all in to take part in the strategic development for this platform to
make new, effective medicines to treat serious unmet medical needs in
CNS disorders and diseases."

About Mario Saltarelli, M.D., Ph.D.

Dr. Mario Saltarelli is a senior vice president of early development and
neurology at Vertex
Pharmaceuticals Incorporated
. Vertex (NASDAQ:VRTX) discovered
and developed the first medicines to treat the underlying cause of
cystic fibrosis (CF), a rare, life-threatening genetic disease. Dr.
Saltarelli leads Vertex's early development activities, including
translational medicine, clinical pharmacology, clinical biomarkers and
neurology. For more than 20 years, Dr. Saltarelli has been focused on
defining, building and successfully advancing development pipelines
through the application of advanced translational paradigms in the
biomedical and pharmaceutical sectors.

Prior to joining Vertex, Dr. Saltarelli served as chief medical officer
at Annexon Biosciences, Inc. and served as the chief science officer and
senior vice president of Mallinckrodt. Dr. Saltarelli served as senior
vice president of clinical development and medical affairs at Shire. His
diverse background spans more than three decades across medical science,
clinical drug development and the scientific and regulatory aspects of
clinical program design. He joined Shire from Abbott Laboratories where
he served as the divisional vice president directly accountable for all
aspects of clinical development, medical affairs and development
strategy for global neuroscience and anesthesia products. Prior to that,
he spent seven years at Pfizer global research and development in
Connecticut, ultimately as an executive director, head of the CNS early
clinical development group. He served as director of MindImmune
Therapeutics. He served for four years as an assistant professor of
neurology at Emory University School of Medicine.

Dr. Saltarelli earned his bachelor of science degree in psychology from
the University of Illinois at Urbana-Champaign, a doctor of medicine
degree and a doctor of philosophy degree in neuropharmacology from The
Johns Hopkins University School of Medicine. He was an intern in
internal medicine at the University of Maryland Medical Center and
completed neurology residency at The Johns Hopkins Hospital.

About Jack Hoppin, Ph.D.

Dr. Jack Hoppin is the co-founder and chief executive officer of Invicro.
Invicro, LLC was founded with the mission of improving the role and
function of imaging in translational drug discovery and development
across all therapeutic areas. Invicro's multi-disciplinary team provides
a full range of image informatics, engineering and operational
services. Prior to co-founding Invicro in 2008, Dr. Hoppin served as the
vice president of imaging systems at Bioscan, Inc. Dr. Hoppin, a
thought-leader in the molecular imaging research and drug development
community, brings 15+ years in experience in the design, development and
commercialization of pre-clinical instrumentation, analytical software
and imaging-based assays. As an active member of the imaging community,
Dr. Hoppin recently serving on the World Molecular Imaging Society Board
of Trustees. He is also a member of the Society of Nuclear Medicine
CMIIT Industry Council and the Harvard Catalyst Faculty.

Dr. Hoppin earned his bachelor of science degree in mathematics with a
minor in physics from the College of the Holy Cross in Worcester, Mass.,
USA, and his master of science degree and doctor of philosophy degree in
applied mathematics from the University of Arizona in Tucson, Ariz.,
USA. Dr. Hoppin worked as an Alexander von Humboldt post-doctoral fellow
in medical physics at the Research Center in Jülich, Germany.

About Sue O'Connor, B.Sc. (Hons), Ph.D.

Dr. Sue O'Connor is currently vice president of neuroscience research at Bionomics
Ltd.
in Adelaide, Australia. Bionomics (ASX: BNO) is a global,
clinical stage biopharmaceutical company leveraging its proprietary
platform technologies to discover and develop a deep pipeline of best in
class, novel drug candidates targeting ion channels. Dr. O'Connor joined
Bionomics in 2003 as a member of the drug discovery team before her
appointment as senior director of central nervous system research and
development. Her role at Bionomics has included a high level of
involvement with the identification of BNC210, a drug candidate with
considerable potential as a new treatment for anxiety disorders and a
collaboration with Merck & Co on a discovery-phase pain program. Dr.
O'Connor's current focus is the development of new drugs to treat
cognitive impairment associated with several disease states. One of
these programs was partnered with Merck & Co in 2014 and is now in early
clinical development. Previously she entered the biotechnology sector
working on drug development projects in the department of
gastroenterology at Flinders Medical Centre. During this time, Dr.
O'Connor's interest in neuro-psychopharmacology and the development of
drugs for the treatment of psychiatric disorders was formed.

Dr. O'Connor earned her doctor of philosophy degree in molecular
genetics from the University of Adelaide, Australia and completed her
post-doctoral research at the Hanson Institute in Adelaide, Australia.

About Bioasis

Bioasis Technologies Inc. is a biopharmaceutical company developing xB3,
a proprietary platform technology for the delivery of therapeutics
across the blood-brain barrier (BBB) and the treatment of CNS disorders,
including brain cancers and neurodegenerative diseases. The delivery of
therapeutics across the BBB represents the final frontier in treating
neurological disorders. The in-house development programs at Bioasis are
designed to develop symptomatic and disease-modifying treatments for
brain-related diseases and disorders. The company maintains headquarters
in Richmond, BC, Canada with offices in Guilford, Conn., United States.
Bioasis trades on the TSX Venture Exchange under the symbol "BTI" and on
the OTCQB under the symbol "BIOAF." For more information about the
company please visit www.bioasis.ca
or www.bioasis.us.

Forward Looking Statements

Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe", "may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements or information involve known and unknown risks, uncertainties
and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any
future results, events or developments express or implied by such
forward-looking statements or information. Such factors include, among
others, our stage of development, lack of any product revenues,
additional capital requirements, risk associated with the completion of
clinical trials and obtaining regulatory approval to market our
products, the ability to protect our intellectual property, dependence
on collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such
actual events or results expressed or implied by such forward-looking
statements and information to differ materially from any future events
or results expressed or implied by such statements and information
include, but are not limited to, the risks and uncertainties that:
products that we develop may not succeed in preclinical or clinical
trials, or future products in our targeted corporate objectives; our
future operating results are uncertain and likely to fluctuate; we may
not be able to raise additional capital; we may not be successful in
establishing additional corporate collaborations or licensing
arrangements; we may not be able to establish marketing and the costs of
launching our products may be greater than anticipated; we have no
experience in commercial manufacturing; we may face unknown risks
related to intellectual property matters; we face increased competition
from pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at
www.sedar.com.
Given these risks and uncertainties, you are cautioned not to place
undue reliance on such forward-looking statements and information, which
are qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update
such forward- looking statements and information to reflect subsequent
events or circumstances, except as required by law.

"Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release"

View Comments and Join the Discussion!